|
Indications and Dosage
Intravenous
Hypertensive crisis Adult: Initially, 25 mg by slow inj over 20 seconds, repeat if necessary after 5 minutes. This may be followed by 50 mg after another 5 minutes if response is insufficient. Continue with a maintenance infusion of 9-30 mg/hr once BP is reduced sufficiently. Oral Hypertension Adult: 30-90 mg bid.
|
|
Hepatic Impairment
Severe: Use with caution.
|
|
Contraindications
Aortic stenosis (IV), lactation.
|
|
Special Precautions
Elderly, severe hepatic insufficiency. Pregnancy.
|
|
Adverse Reactions
Dizziness, nausea, headache, fatigue, orthostatic hypotension, palpitations, nervousness, pruritus and allergic skin reactions.
|
|
Drug Interactions
Increased risk of hypotension with other antihypertensives. Decreased antihypertensive effect with NSAIDs.
|
|
Action
Description: Urapidil is a centrally acting antihypertensive that blocks peripheral α1-adrenoceptors. It reduces peripheral resistance which leads to a fall in systolic and diastolic BP, without reflex tachycardia.
Pharmacokinetics: Absorption: Rapidly absorbed. Bioavailability: 70-80%. Distribution: Protein binding: 80% Metabolism: Extensively metabolised in liver, mainly by hydroxylation. Elimination half-life: 4.7 hr (oral) and 2.7 hr (IV). Excretion: Excreted in urine as metabolites and unchanged drug (10-20%) |
|
MIMS Class
|
Sign Out
